Clinical Trial Update: Trial of Cabozantinib (XL184) in Castrate-Resistant Prostate Cancer Metastatic to Bone [Phase 2]

View source ↗

Summary

A Phase 2 trial of cabozantinib in metastatic castration-resistant prostate cancer with bone metastases was terminated, and results have been posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• cabozantinib (cabozantinib)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Prostate Cancer Metastatic | Phase 2 | Status: TERMINATED | Results posted: 2016-05-02